Glycoconjugate vaccine strategies for protection against invasive Salmonella infections

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 4, 2012, Pages 486-490

  Simon, Raphael ^a,b   Levine, Myron M ^a,b  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Conjugate vaccine; Non typhoidal salmonella; O polysaccharide; Paratyphoid; Polysaccharide vaccine; Salmonella; Typhoid; Vi

Indexed keywords

ANTIGEN; BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; CARRIER PROTEIN; DIPHTHERIA TOXOID; DIPHTHERIA TOXOID CRM197; FLAGELLIN; POLYSACCHARIDE VACCINE; PORIN; SALMONELLA GLYCOCONJUGATE VACCINE; SALMONELLOSIS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; BACTERIAL VACCINE; VACCINE;

AFRICA SOUTH OF THE SAHARA; BACTERIAL MEMBRANE; DRUG CONJUGATION; DRUG EFFICACY; GASTROENTERITIS; HOST; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL MEMORY; INDUSTRIALIZATION; NONHUMAN; NOTE; SALMONELLA ENTERICA; SALMONELLA ENTERITIDIS; SALMONELLA PARATYPHI; SALMONELLA PARATYPHI B; SALMONELLA TYPHI; SALMONELLOSIS; SEROTYPE; TYPHOID FEVER; ANIMAL; ANIMAL SALMONELLOSIS; BACTEREMIA; DRUG DEVELOPMENT; IMMUNOLOGY; REVIEW;

ANIMALS; BACTEREMIA; BACTERIAL VACCINES; DRUG DISCOVERY; HUMANS; POLYSACCHARIDES, BACTERIAL; SALMONELLA INFECTIONS; SALMONELLA INFECTIONS, ANIMAL; VACCINES, CONJUGATE;

EID: 84872029523     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.8.4     Document Type: Note

References (63)

1. Ferreccio C, Levine MM, Manterola A, Rodriguez G, Rivara I, Prenzel I, et al. Benign bacteremia caused by Salmonella typhi and paratyphi in children younger than 2 years. J Pediatr 1984; 104:899-901; PMID:6427437; http://dx.doi.org/10.1016/S0022-3476(84)80492-8.
2. Owais A, Sultana S, Zaman U, Rizvi A, Zaidi AK. Incidence of typhoid bacteremia in infants and young children in Southern coastal Pakistan. Pediatr Infect Dis J 2010; 29:1035-9; PMID:21046701.
3. Chiu CH, Chuang CH, Chiu S, Su LH, Lin TY. Salmonella enterica serotype choleraesuis infections in pediatric patients. Pediatrics 2006; 117:1193-6; PMID:16717121; http://dx.doi.org/10.1542/peds.2005-251.
4. Chiu CH, Wu TL, Su LH, Liu JW, Chu C. Fluoroquinolone resistance in Salmonella enterica serotype choleraesuis, Taiwan 2000-3. Emerg Infect Dis 2004; 10:1674-6; PMID:15498176.
5. Chiu S, Chiu CH, Lin TY. Salmonella enterica serotype choleraesuis infection in a medical center in northern Taiwan. J Microbiol Immunol Infect 2004; 37:99-102; PMID:15181491.
6. Kazemi M, Gumpert G, Marks MI. Clinical spectrum and carrier state of nontyphoidal Salmonella infections in infants and children. Can Med Assoc J 1974; 110:1253-7; PMID:4857958.
7. Nelson SJ, Granoff D. Salmonella gastroenteritis in the first three months of life. A review of management and complications. Clin Pediatr (Phila) 1982; 21:709-12; PMID:7140121; http://dx.doi.org/10.1177/000992288202101201.
8. Kuppermann N. Occult bacteremia in young febrile children. Pediatr Clin North Am1999; 46:1073-109; PMID:10629675; http://dx.doi.org/10.1016/S0031- 3955(05)70176-0.
9. Vugia DJ, Samuel M, Farley MM, Marcus R, Shiferaw B, Shallow S, et al.; Emerging Infections Program FoodNet Working Group. Invasive Salmonella infections in the United States, FoodNet, 1996-1999: incidence, serotype distribution and outcome. Clin Infect Dis 2004; 38:149-56; PMID:15095184; http://dx.doi.org/10.1086/381581.
10. Berkley JA, Lowe BS, Mwangi I, Williams T, Bauni E, Mwarumba S, et al. Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 2005; 352:39-47; PMID:15635111; http://dx.doi.org/10.1056/NEJMoa040275.
11. Kariuki S, Revathi G, Kariuki N, Kiiru J, Mwituria J, Muyodi J, et al. Invasive multidrug-resistant nontyphoidal Salmonella infections in Africa: zoonotic or anthroponotic transmission? J Med Microbiol 2006; 55:585-91; PMID:16585646; http://dx.doi.org/10.1099/jmm.0.46375-0.
12. Kariuki S, Revathi G, Kariuki N, Kiiru J, Mwituria J, Hart CA. Characterisation of community acquired non-typhoidal Salmonella from bacteraemia and diarrhoeal infections in children admitted to hospital in Nairobi, Kenya. BMC Microbiol 2006; 6:101; PMID:17173674; http://dx.doi.org/10.1186/1471-2180-6- 101.
13. Mandomando I, Macete E, Sigaúque B, Morais L, Quintó L, Sacarlal J, et al. Invasive non-typhoidal Salmonella in Mozambican children. Trop Med Int Health 2009; 14:1467-74; PMID:19793081; http://dx.doi.org/10.1111/ j.1365-3156.2009.02399.x.
14. Walsh AL, Phiri AJ, Graham SM, Molyneux EM, Molyneux ME. Bacteremia in febrile Malawian children: clinical and microbiologic features. Pediatr Infect Dis J 2000; 19:312-8; PMID:10783021; http://dx.doi.org/10.1097/00006454- 200004000-00010.
15. Enwere G, Biney E, Cheung YB, Zaman SM, Okoko B, Oluwalana C, et al. Epidemiologic and clinical characteristics of community-acquired invasive bacterial infections in children aged 2-29 months in The Gambia. Pediatr Infect Dis J 2006; 25:700-5; PMID:16874169; http://dx.doi.org/10.1097/01.inf. 0000226839.30925.a5.
16. Tennant SM, Diallo S, Levy H, Livio S, Sow SO, Tapia M, et al. Identification by PCR of nontyphoidal Salmonella enterica serovars associated with invasive infections among febrile patients in Mali. PLoS Negl Trop Dis 2010; 4:621; PMID:20231882; http://dx.doi.org/10.1371/journal.pntd.0000621.
17. Wilson RP, Winter SE, Spees AM, Winter MG, Nishimori JH, Sanchez JF, et al. The Vi capsular polysaccharide prevents complement receptor 3-mediated clearance of Salmonella enterica serotype Typhi. Infect Immun 2011; 79:830-7; PMID:21098104; http://dx.doi.org/10.1128/IAI.00961-10.
18. Robbins JD, Robbins JB. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis 1984; 150:436-49; PMID:6207249; http://dx.doi.org/10.1093/infdis/150.3.436.
19. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996; 14:435-8; PMID:8735556; http://dx.doi.org/10.1016/0264-410X(95)00186-5.
20. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with proteinpolysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9:213-20; PMID:19214194; http://dx.doi.org/10.1038/nri2494.
21. Szu SC, Taylor DN, Trofa AC, Clements JD, Shiloach J, Sadoff JC, et al. Laboratory and preliminary clinical characterization of Vi capsular polysaccharideprotein conjugate vaccines. Infect Immun 1994; 62:4440-4; PMID:7927707.
22. Kossaczka Z, Lin FY, Ho VA, Thuy NT, Van Bay P, Thanh TC, et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers and 2- to 4-year-old children in Vietnam. Infect Immun 1999; 67:5806-10; PMID:10531232.
23. Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344:1263-9; PMID:11320385; http://dx.doi.org/10.1056/ NEJM200104263441701.
24. Mai NL, Phan VB, Vo AH, Tran CT, Lin FY, Bryla DA, et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med 2003; 349:1390-1; PMID:14523155; http://dx.doi.org/10.1056/ NEJM200310023491423.
25. Canh DG, Lin FY, Thiem VD, Trach DD, Trong ND, Mao ND, et al. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect Immun 2004; 72:6586-8; PMID:15501790; http://dx.doi.org/10.1128/IAI.72.11.6586-8.2004.
26. Thiem VD, Lin FY, Canh G, Son NH, Anh DD, Mao ND, et al. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol 2011; 18:730-5; PMID:21411598; http://dx.doi.org/10.1128/CVI.00532-10.
27. Cui C, Carbis R, An SJ, Jang H, Czerkinsky C, Szu SC, et al. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates. Clin Vaccine Immunol 2010; 17:73-9; PMID:19889941; http://dx.doi.org/10.1128/CVI.00266-09.
28. Micoli F, Rondini S, Pisoni I, Proietti D, Berti F, Costantino P, et al. Vi-CRM 197 as a new conjugate vaccine against Salmonella typhi. Vaccine 2011; 29:712-20; PMID:21115057; http://dx.doi.org/10.1016/j.vaccine.2010.11.022.
29. van Damme P, Kafeja F, Anemona A, Basile V, Hilbert AK, De Coster I, et al. Safety, immunogenicity and dose ranging of a new Vi-CRM197 conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PLoS One 2011; 6:25398; PMID:21980445; http://dx.doi.org/10.1371/journal.pone.0025398.
30. Shah N. Indian Vi conjugate typhoid vaccine: misleading claims. Indian Pediatr 2010; 47:447; PMID:20519792; http://dx.doi.org/10.1007/s13312-010-0068- 4.
31. Shah NK. Indian conjugate Vi typhoid vaccine: do we have enough evidence? Indian Pediatr 2009; 46:181-2; PMID:19242041.
32. Mathew JL. Conjugate typhoid vaccine(s) in the Indian context. Indian Pediatr 2009; 46:182-4; PMID:19242042.
33. Arya SC. Salmonella typhi Vi antigen-negative isolates in India and prophylactic typhoid immunization. Natl Med J India2000; 13:220; PMID:11002694.
34. Arya SC. Efficacy of Vi polysaccharide vaccine against Salmonella typhi. Vaccine 1999; 17:1015-6; PMID:10195609.
35. Baker S, Sarwar Y, Aziz H, Haque A, Ali A, Dougan G, et al. Detection of Vi-negative Salmonella enterica serovar typhi in the peripheral blood of patients with typhoid fever in the Faisalabad region of Pakistan. J Clin Microbiol 2005; 43:4418-25; PMID:16145086; http://dx.doi.org/10.1128/JCM.43.9. 4418-25.2005.
36. Lindberg AA, Le Minor L. Serology of Salmonella. In: Bergan T, Ed. Methods in Microbiology: Academic Press 1984; 1-141.
37. Konadu E, Shiloach J, Bryla DA, Robbins JB, Szu SC. Synthesis, characterization and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls. Infect Immun 1996; 64:2709-15; PMID:8698499.
38. Hellerqvist CG, Lindberg B, Samuelsson K, Lindberg AA. Structural studies on the O-specific side-chains of the cell-wall lipopolysaccharide from Salmonella parathyphi A var. durazzo. Acta Chem Scand 1971; 25:955-61; PMID:5117491; http://dx.doi.org/10.3891/acta.chem.scand.25-0955.
39. Grimont PAD, Weill FX. Antigenic formulae of the Salmonella serovars. WHO Collaborating Centre for Reference and Research on Salmonella 2007; 1-166.
40. Slauch JM, Mahan MJ, Michetti P, Neutra MR, Mekalanos JJ. Acetylation (O-factor 5) affects the structural and immunological properties of Salmonella typhimurium lipopolysaccharide O antigen. Infect Immun 1995; 63:437-41; PMID:7529745.
41. Ronholm J, Zhang Z, Cao X, Lin M. Monoclonal antibodies to lipopolysaccharide antigens of Salmonella enterica serotype typhimurium DT104. Hybridoma (Larchmt) 2011; 30:43-52; PMID:21466285; http://dx.doi.org/10.1089/ hyb.2010.0066.
42. Heffernan EJ, Harwood J, Fierer J, Guiney D. The Salmonella typhimurium virulence plasmid complement resistance gene rck is homologous to a family of virulence-related outer membrane protein genes, including pagC and ail. J Bacteriol 1992; 174:84-91; PMID:1729227.
43. Grossman N, Schmetz MA, Foulds J, Klima EN, Jimenez-Lucho VE, Leive LL, et al. Lipopolysaccharide size and distribution determine serum resistance in Salmonella montevideo. J Bacteriol 1987; 169:856-63; PMID:2433267.
44. Liang-Takasaki CJ, Grossman N, Leive L. Salmonellae activate complement differentially via the alternative pathway depending on the structure of their lipopolysaccharide O-antigen. J Immunol 1983; 130:1867-70; PMID:6187823.
45. Liang-Takasaki CJ, Saxén H, Mäkelä PH, Leive L. Complement activation by polysaccharide of lipopolysaccharide: an important virulence determinant of Salmonellae. Infect Immun 1983; 41:563-9; PMID:6347890.
46. Gondwe EN, Molyneux ME, Goodall M, Graham SM, Mastroeni P, Drayson MT, et al. Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans. Proc Natl Acad Sci USA 2010; 107:3070-5; PMID:20133627; http://dx.doi.org/10.1073/pnas.0910497107.
47. MacLennanCA, GondweEN, MsefulaCL, KingsleyRA, ThomsonNR, WhiteSA, et al. The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children.J Clin Invest2008; 118:1553-62; PMID:18357343; http://dx.doi.org/10.1172/JCI33998.
48. Casadevall A, Pirofski LA. A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv Immunol 2006; 91:1-44; PMID:16938537; http://dx.doi.org/10.1016/S0065-2776(06) 91001-3.
49. Colwell DE, Michalek SM, Briles DE, Jirillo E, McGhee JR. Monoclonal antibodies to Salmonella lipopolysaccharide: anti-O-polysaccharide antibodies protect C3H mice against challenge with virulent Salmonella typhimurium. J Immunol 1984; 133:950-7; PMID:6203984.
50. Carlin NI, Svenson SB, Lindberg AA. Role of monoclonal O-antigen antibody epitope specificity and isotype in protection against experimental mouse typhoid. Microb Pathog 1987; 2:171-83; PMID:2467161; http://dx.doi.org/10.1016/ 0882-4010(87)90019-2.
51. Michetti P, Mahan MJ, Slauch JM, Mekalanos JJ, Neutra MR. Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen Salmonella typhimurium. Infect Immun 1992; 60:1786-92; PMID:1373399.
52. Svenson SB, Lindberg AA. Artificial Salmonella vaccines: Salmonella typhimurium O-antigen-specific oligosaccharide-protein conjugates elicit protective antibodies in rabbits and mice. Infect Immun 1981; 32:490-6; PMID:6166555.
53. Svenson SB, Nurminen M, Lindberg AA. Artificial Salmonella vaccines: O-antigenic oligosaccharide-protein conjugates induce protection against infection with Salmonella typhimurium. Infect Immun 1979; 25:863-72; PMID:387597.
54. MacLennan CA, Gilchrist JJ, Gordon MA, Cunningham AF, Cobbold M, Goodall M, et al. Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-infected African adults. Science 2010; 328:508-12; PMID:20413503; http://dx.doi.org/10.1126/science.1180346.
55. Roantree RJ, Rantz LA. A Study of the Relationship of the Normal Bactericidal Activity of Human Serum to Bacterial Infection. J Clin Invest 1960; 39:72-81; PMID:16695824; http://dx.doi.org/10.1172/JCI104029.
56. Polish Typhoid Committee. Controlled field trials and laboratory studies on the effectiveness of typhoid vaccines in Poland, 1961-4. Bull World Health Organ 1966; 34:211-22; PMID:5296128.
57. Hejfec LBSL, Salmin LV, Lejtman MZ, Kuz'minova ML, Vasil'eva AV, Levina LA, et al. A controlled field trial and laboratory study of five typhoid vaccines in the USSR. Bull World Health Organ 1966; 34:321-39; PMID:5296393.
58. Simon R, Tennant SM, Wang JY, Schmidlein PJ, Lees A, Ernst RK, et al. Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis. Infect Immun 2011; 79:4240-9; PMID:21807909; http://dx.doi.org/10.1128/IAI.05484-11.
59. Watson DC, Robbins JB, Szu SC. Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect Immun 1992; 60:4679-86; PMID:1383154.
60. Jörbeck HJ, Svenson SB, Lindberg AA. Artificial Salmonella vaccines: Salmonella typhimurium O-antigen-specific oligosaccharide-protein conjugates elicit opsonizing antibodies that enhance phagocytosis. Infect Immun 1981; 32:497-502; PMID:7019072.
61. Konadu EY, Lin FY, Hó VA, Thuy NT, Van Bay P, Thanh TC, et al. Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers and 2- to 4-year-old children in Vietnam. Infect Immun 2000; 68:1529-34; PMID:10678970; http://dx.doi.org/10.1128/IAI.68.3.1529-34.2000.
62. Tennant SM, Wang JY, Galen JE, Simon R, Pasetti MF, Gat O, et al. Engineering and preclinical evaluation of attenuated nontyphoidal Salmonella strains serving as live oral vaccines and as reagent strains. Infect Immun 2011; 79:4175-85; PMID:21807911; http://dx.doi.org/10.1128/IAI.05278-11.
63. Song L, Nakaar V, Kavita U, Price A, Huleatt J, Tang J, et al. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS One 2008; 3:2257; PMID:18493310; http://dx.doi.org/10.1371/journal.pone.0002257.